Karsten Eastman, CEO of Sethera Therapeutics whose discovery could be especially useful for enhancing GLP-1 medications such as semaglutide, the active ingredient in Ozempic and Wegovy, which are widely used to treat diabetes and obesity joins eHealth Radio and the Health News Channel.

Listen to host Eric Dye & guest Karsten Eastman discuss the following:

For listeners who are not scientists, what exactly was discovered here, and why are researchers excited about it?
What are peptide drugs, and why are they so important in treatments for diabetes and obesity?
What specifically could this discovery do for GLP-1 drugs like semaglutide? Could this eventually mean fewer injections or lower doses for patients?
Could this enzyme technology be used for diseases beyond diabetes and obesity?
How transformative could enzymatic drug engineering become over the next decade, what could medicine look like 10 years from now?

About Karsten Eastman

Dr. Karsten Eastman received a PhD from the University of Utah under the mentorship of Professor Vahe Bandarian, where they discovered the key processes that enable Sethera Therapeutics’ innovative technology.  As a co-founder of Sethera, Dr. Eastman is leading the company’s efforts to commercialize cutting-edge peptide therapeutics, drawing on their experience in enzyme and peptide research, patent development, and engagement with key business mentors.

About Sethera Therapeutics

Founded by University of Utah chemists Vahe Bandarian and Karsten Eastman, Sethera Therapeutics is revolutionizing peptide-based drug development with its enzymatic cross-linking technology. Their platform enables the synthesis of highly stable, polymacrocyclic peptides designed to engage with single targets or multiple targets simultaneously, offering unparalleled precision in therapeutic design. The technology was first developed at the University of Utah with NIH funding and licensed exclusively to Sethera Therapeutics.

Website: https://setheratx.com

Social Media Links:
Linkedin: linkedin.com/company/sethera-therapeutics
X: @SetheraTx